Medicine and Dentistry
Transplantation
77%
Kidney Graft
75%
Kidney Transplantation
50%
Biopsy
48%
Allograft
48%
Kidney Allograft
33%
COVID-19
31%
Immunosuppressive Treatment
28%
Injury
27%
Acute Graft Rejection
24%
Graft Failure
20%
Biological Marker
19%
Solid Organ Transplantation
18%
Antibody Mediated Rejection
17%
Graft Survival
17%
Immunosuppressive Drug
14%
Organ Transplantation
14%
Nephropathy
14%
Organ Donor
12%
T Cell
11%
Clinical Trial
11%
Fibrosis
10%
Diagnosis
9%
Infection
9%
Graft Rejection
9%
Antibodies
9%
BK Virus
9%
Human Immunodeficiency Virus
9%
Disease
9%
End Stage Renal Disease
8%
Kidney Function
8%
Tacrolimus
8%
Complement Component C4d
8%
Chronic Allograft Nephropathy
8%
Epileptic Absence
8%
Retrospective Cohort Study
7%
Calcineurin Inhibitor
7%
Hazard Ratio
7%
HLA Antibody
7%
Immune Response
7%
Drug Therapy
6%
Cytochrome P450 3A5
6%
Gene Expression
6%
Observational Study
6%
Creatinine
6%
Cytokine
6%
Apolipoprotein L1
5%
Cell-Free DNA
5%
Gender and Sex
5%
Deterioration
5%
Immunology and Microbiology
Transplant Procedure
100%
Allotransplantation
67%
Acute Graft Rejection
31%
Kidney Transplantation
29%
Tacrolimus
26%
Mouse
22%
T Cell
20%
Immunosuppression
18%
Immunosuppressive Drug
16%
Allele
10%
Solid Organ Transplantation
10%
COVID-19
10%
Creatinine Blood Level
9%
Immune Response
9%
Transplant Rejection
9%
Complement Component C4d
8%
Kidney Allograft Rejection
8%
Lymphocyte
8%
Antibody Mediated Rejection
8%
Monospecific Antibody
8%
BK Virus
7%
Human Immunodeficiency Virus
7%
Genetic Variability
7%
Cytokine
7%
Kidney Graft Rejection
6%
T Cell Depletion
6%
Mouse Model
6%
Kidney Function
6%
Immune System
5%
Next Generation Sequencing
5%
Transplantation Research
5%
CD8
5%
Adaptive Immune System
5%
Sirolimus
5%
Trough Concentration
5%
Keyphrases
Kidney Transplant Recipients
23%
Kidney Transplantation
20%
Tacrolimus
15%
Transplantation
14%
Acute Rejection
11%
Allograft
11%
COVID-19
11%
CYP3A5
11%
Kidney Allograft
11%
Coronavirus Disease (COVID)
10%
Kidney Transplant
9%
Solid Organ Transplant Recipients
8%
Immunosuppression
8%
Renal Transplantation
8%
African American
7%
Fibrosis
7%
Graft Loss
7%
Inflammation
7%
Chronic Antibody-mediated Rejection
7%
Renal Allograft Rejection
6%
Graft Function
6%
Transplant Outcomes
6%
Genotype
6%
Death-censored Graft Survival
6%
Solid Organ Transplantation
6%
Clinical Trials
6%
Chronic Allograft Injury
5%
COVID-19 Outcomes
5%
Area under the Curve
5%
T Cells
5%
Banff
5%
Kidney
5%
Confidence Interval
5%
Immune Response
5%
Major Adverse Renal Events
5%